Products

Out-Licensing
Active Ingredients
Contract Manufacturing
Download Product list
Product Family Name
Dosage Form
Dosage Strength
Development Status
Dossier Readiness
ATC Group
4B Zone Stability*
Available Territory
No results matching you criteria!

ABACAVIR SULFATE + LAMIVUDINE

Dosage Form:
Film-coated tablet
Dosage Strength:
600 mg + 300 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Anti-infectives for systemic use
4B Zone Stability*:
No
Available Territory:
Global

ABIRATERONE ACETATE

Dosage Form:
Film-coated tablet
Dosage Strength:
500 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Antineoplastic and immunomodulating agents
4B Zone Stability*:
Yes
Available Territory:
Global

ACETYLSALICYLIC ACID

Dosage Form:
Tablet
Dosage Strength:
50 mg, 100 mg
Development Status:
Ongoing
Dossier Readiness:
Q3 2023
ATC Group:
Various ATC structures
4B Zone Stability*:
No
Available Territory:
Europe

AGOMELATINE

Dosage Form:
Film-coated tablet
Dosage Strength:
25 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Antidepressant
4B Zone Stability*:
Can be added
Available Territory:
Global

AMLODIPINE

Dosage Form:
Tablet
Dosage Strength:
2.5 mg, 5 mg, 10 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
Yes
Available Territory:
Europe

AMLODIPINE BESILATE + CANDESARTAN CILEXETIL

Dosage Form:
Tablet
Dosage Strength:
5 mg + 8 mg, 10 mg + 16 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Europe

AMLODIPINE BESILATE + CANDESARTAN CILEXETIL

Dosage Form:
Tablet
Dosage Strength:
5 mg + 16 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Global

AMLODIPINE BESILATE + INDAPAMIDE + PERINDOPRIL ERBUMINE

Dosage Form:
Tablet
Dosage Strength:
5 mg + 1.25 mg + 4 mg, 10 mg + 1.25 mg + 4 mg, 5 mg + 2.5 mg + 8 mg, 10 mg + 2.5 mg + 8 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Global

AMLODIPINE BESILATE + PERINDOPRIL ERBUMINE

Dosage Form:
Tablet
Dosage Strength:
5 mg + 4 mg, 10 mg + 4 mg, 5 mg + 8 mg, 10 mg + 8 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Global

AMLODIPINE BESILATE + VALSARTAN

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg + 80 mg, 5 mg + 160 mg, 10 mg + 160 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Europe

APIXABAN

Dosage Form:
Film-coated tablet
Dosage Strength:
2.5 mg, 5 mg
Development Status:
Ready
Dossier Readiness:
Filed in EU
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
No
Available Territory:
Europe

APREMILAST

Dosage Form:
Film-coated tablet
Dosage Strength:
10 mg, 20 mg, 30 mg
Development Status:
Ongoing
Dossier Readiness:
Q1 2023
ATC Group:
Dermatological drugs
4B Zone Stability*:
At risk
Available Territory:
Global

ATORVASTATIN CALCIUM

Dosage Form:
Film-coated tablet
Dosage Strength:
10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg
Development Status:
Ready
Dossier Readiness:
Q4 2022
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Europe

BISOPROLOL FUMARATE

Dosage Form:
Tablet
Dosage Strength:
1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Global

CAPSULES

Dosage Form:
-
Dosage Strength:
-
Development Status:
-
Dossier Readiness:
-
ATC Group:
-
4B Zone Stability*:
-
Available Territory:
-

CLOPIDOGREL BISULPHATE

Dosage Form:
Film-coated tablet
Dosage Strength:
75 mg
Development Status:
Ongoing
Dossier Readiness:
Q1 2023
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
Can be added
Available Territory:
Global

DAPAGLIFLOZIN

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg, 10 mg
Development Status:
Ongoing
Dossier Readiness:
Q3 2024
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
Can be added
Available Territory:
Global

DAPAGLIFLOZIN + METFORMIN

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg + 850 mg, 5 mg + 1000 mg
Development Status:
Ongoing
Dossier Readiness:
Q4 2025
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
Can be added
Available Territory:
Global

DEFERASIROX

Dosage Form:
Film-coated tablet
Dosage Strength:
90 mg, 180 mg, 360 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Various ATC structures
4B Zone Stability*:
No
Available Territory:
Global

DROSPIRENONE + ESTRADIOL

Dosage Form:
Film-coated tablet
Dosage Strength:
2 mg + 1 mg
Development Status:
Ready
Dossier Readiness:
Q1 2023
ATC Group:
Hormone replacement therapy
4B Zone Stability*:
No
Available Territory:
Europe

DULOXETINE HYDROCHLORIDE

Dosage Form:
Capsule hard gastro-resistant
Dosage Strength:
30 mg, 60 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Nervous system
4B Zone Stability*:
No
Available Territory:
Global

DULOXETINE HYDROCHLORIDE

Dosage Form:
Capsule hard gastro-resistant
Dosage Strength:
20 mg, 40 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Urology
4B Zone Stability*:
No
Available Territory:
Europe

EDOXABAN

Dosage Form:
Film-coated tablet
Dosage Strength:
15 mg, 30 mg, 60 mg
Development Status:
Ongoing
Dossier Readiness:
Q3 2023
ATC Group:
Cardiovascular system
4B Zone Stability*:
Can be added
Available Territory:
Global

EMPAGLIFLOZIN

Dosage Form:
Film-coated tablet
Dosage Strength:
10 mg, 25 mg
Development Status:
Ongoing
Dossier Readiness:
Q3 2025
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
Can be added
Available Territory:
Global

EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE

Dosage Form:
Film-coated tablet
Dosage Strength:
200 mg + 25 mg + 25 mg, 200 mg + 27.5 mg + 28 mg
Development Status:
Ongoing
Dossier Readiness:
Q2 2024
ATC Group:
Antivirotic
4B Zone Stability*:
Can be added
Available Territory:
Global

EMTRICITABINE + TENOFOVIR ALAFENAMIDE

Dosage Form:
Film-coated tablet
Dosage Strength:
200 mg + 10 mg, 200 mg + 25 mg
Development Status:
Ongoing
Dossier Readiness:
Q1 2024
ATC Group:
Antivirotic
4B Zone Stability*:
Can be added
Available Territory:
Global

ENZALUTAMIDE

Dosage Form:
Film-coated tablet
Dosage Strength:
40 mg, 80 mg
Development Status:
Ongoing
Dossier Readiness:
Q2 2025
ATC Group:
Antineoplastic and immunomodulating agents
4B Zone Stability*:
Can be added
Available Territory:
Global

ETORICOXIB

Dosage Form:
Film-coated tablet
Dosage Strength:
30 mg, 60 mg, 90 mg, 120 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Musculoskeletal system
4B Zone Stability*:
No
Available Territory:
Europe

FINGOLIMOD

Dosage Form:
Capsule, hard
Dosage Strength:
0.5 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Multiple sclerosis
4B Zone Stability*:
No
Available Territory:
Europe

HYDROCHLOROTHIAZIDE + TELMISARTAN

Dosage Form:
Tablet
Dosage Strength:
12.5 mg + 40 mg, 12.5 mg + 80 mg, 25 mg + 80 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Global

HYDROCHLOROTHIAZIDE+ LOSARTAN POTASSIUM

Dosage Form:
Film-coated tablet
Dosage Strength:
12.5 mg + 50 mg, 12.5 mg + 100 mg, 25 mg + 100 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Global

IBANDRONATE SODIUM MONOHYDRATE

Dosage Form:
Film-coated tablet
Dosage Strength:
150 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Musculoskeletal system
4B Zone Stability*:
No
Available Territory:
Europe

IBRUTINIB

Dosage Form:
Film-coated tablet
Dosage Strength:
140 mg, 280 mg, 420 mg, 560 mg
Development Status:
Ongoing
Dossier Readiness:
Q2 2025
ATC Group:
Antineoplastic and immunomodulating agents
4B Zone Stability*:
Can be added
Available Territory:
Global

IBRUTINIB

Dosage Form:
Film-coated tablet
Dosage Strength:
140 mg, 280 mg, 420 mg, 560 mg
Development Status:
Ongoing
Dossier Readiness:
Q2 2025
ATC Group:
Antineoplastic and immunomodulating agents
4B Zone Stability*:
Can be added
Available Territory:
Global

IBUPROFEN

Dosage Form:
Film-coated tablet
Dosage Strength:
200 mg, 400 mg, 600 mg, 800 mg
Development Status:
Ready
Dossier Readiness:
Filed in EU
ATC Group:
Nervous system
4B Zone Stability*:
No
Available Territory:
Global

ILOPROST

Dosage Form:
Nebuliser solution
Dosage Strength:
10 μg / 1 ml
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
No
Available Territory:
Europe

ILOPROST

Dosage Form:
Nebuliser solution
Dosage Strength:
20 μg / 1 ml
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
Yes
Available Territory:
Global

ILOPROST

Dosage Form:
Solution for injection
Dosage Strength:
100 μg / 1 ml (0.5 ml)
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
No
Available Territory:
Global

LACOSAMIDE

Dosage Form:
Film-coated tablet
Dosage Strength:
50 mg, 100 mg 150 mg, 200 mg
Development Status:
Ongoing
Dossier Readiness:
Q2 2023
ATC Group:
Nervous system
4B Zone Stability*:
Yes
Available Territory:
Global

LEVETIRACETAM

Dosage Form:
Film-coated tablet
Dosage Strength:
250 mg, 500 mg, 750 mg, 1000 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Nervous system
4B Zone Stability*:
No
Available Territory:
Global

LINAGLIPTIN

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
No
Available Territory:
Europe

LOPERAMIDE

Dosage Form:
Capsule
Dosage Strength:
2 mg
Development Status:
Ongoing
Dossier Readiness:
Q4 2023
ATC Group:
Antipropulsive
4B Zone Stability*:
Can be added
Available Territory:
Global

METAMIZOLE SODIUM

Dosage Form:
Film-coated tablet
Dosage Strength:
500 mg
Development Status:
Ready
Dossier Readiness:
Filed in EU
ATC Group:
Nervous system
4B Zone Stability*:
Yes
Available Territory:
To be discussed

METAMIZOLE SODIUM

Dosage Form:
Injection
Dosage Strength:
500 mg/ml (2 ml)
Development Status:
Ready
Dossier Readiness:
To be filed in October
ATC Group:
Nervous system
4B Zone Stability*:
Can be added
Available Territory:
To be discussed

METFORMIN HYDROCHLORIDE

Dosage Form:
Film-coated tablet
Dosage Strength:
500 mg, 850 mg, 1000 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
Yes
Available Territory:
Global

NOREPINEPHRINE

Dosage Form:
Injection
Dosage Strength:
1 mg / 1 ml
Development Status:
Ongoing
Dossier Readiness:
Q4 2023
ATC Group:
Cardiovascular system
4B Zone Stability*:
At risk
Available Territory:
Global

PARACETAMOL

Dosage Form:
Tablet
Dosage Strength:
500 mg, 1000 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Nervous system
4B Zone Stability*:
Yes
Available Territory:
Global

PERINDOPRIL ARGININE

Dosage Form:
Film-coated tablet
Dosage Strength:
2.5 mg, 5 mg, 10 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Global

PRASUGREL HYDROCHLORIDE

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg, 10 mg
Development Status:
Ready
Dossier Readiness:
Q2 2023
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
Yes
Available Territory:
Global

RAMIPRIL

Dosage Form:
Tablet
Dosage Strength:
1.25 mg, 2.5 mg, 5 mg, 10 mg
Development Status:
Ongoing
Dossier Readiness:
Q1 2024
ATC Group:
Cardiovascular system
4B Zone Stability*:
Can be added
Available Territory:
Global

RILMENIDINE

Dosage Form:
Tablet
Dosage Strength:
1 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Europe

RIVAROXABAN

Dosage Form:
Film-coated tablet
Dosage Strength:
2.5 mg, 10 mg, 15 mg, 20 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
No
Available Territory:
Europe

RIVAROXABAN

Dosage Form:
Capsule, hard
Dosage Strength:
2.5 mg, 10 mg, 15 mg, 20 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
No
Available Territory:
Europe

ROSUVASTATIN CALCIUM

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg, 10 mg, 15mg, 20 mg, 30 mg, 40 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Cardiovascular system
4B Zone Stability*:
Yes
Available Territory:
Europe

SACUBITRIL + VALSARTAN

Dosage Form:
Film-coated tablet
Dosage Strength:
24 mg + 26 mg, 49 mg + 51 mg, 97 mg + 103 mg
Development Status:
Ongoing
Dossier Readiness:
Q3 2023
ATC Group:
Cardiovascular system
4B Zone Stability*:
No
Available Territory:
Europe

SERTRALINE

Dosage Form:
Film-coated tablet
Dosage Strength:
25 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Nervous system
4B Zone Stability*:
No
Available Territory:
Global

SERTRALINE

Dosage Form:
Film-coated tablet
Dosage Strength:
50 mg, 100 mg
Development Status:
Ready
Dossier Readiness:
To be filed in November
ATC Group:
Nervous system
4B Zone Stability*:
No
Available Territory:
Global

SITAGLIPTIN PHOSPHATE

Dosage Form:
Film-coated tablet
Dosage Strength:
25 mg, 50 mg, 100 mg
Development Status:
Ready
Dossier Readiness:
Filed in EU
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
Can be added
Available Territory:
Global

SITAGLIPTIN PHOSPHATE + METFORMIN

Dosage Form:
Film-coated tablet
Dosage Strength:
50 mg + 850 mg, 50 mg + 1000 mg
Development Status:
Ongoing
Dossier Readiness:
Q4 2022
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
Can be added
Available Territory:
Global

SOLIFENACIN SUCCINATE

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg, 10 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Genitourinary system and reproductive hormones
4B Zone Stability*:
No
Available Territory:
Europe

TAMSULOSIN HYDROCHLORIDE

Dosage Form:
Modified-release capsule, hard
Dosage Strength:
0.4 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Genitourinary system and reproductive hormones
4B Zone Stability*:
No
Available Territory:
Global

TICAGRELOR

Dosage Form:
Film-coated tablet
Dosage Strength:
60 mg, 90 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Blood and blood forming organs
4B Zone Stability*:
Yes
Available Territory:
Global

TORASEMIDE

Dosage Form:
Tablet
Dosage Strength:
2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg, 100mg, 200mg
Development Status:
Ready
Dossier Readiness:
Filed in EU
ATC Group:
Cardiovascular system
4B Zone Stability*:
Yes
Available Territory:
Global

VARDENAFIL HYDROCHLORIDE TRIHYDRATE

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg, 10 mg, 20 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Genitourinary system and reproductive hormones
4B Zone Stability*:
No
Available Territory:
Europe

VILDAGLIPTIN

Dosage Form:
Tablet
Dosage Strength:
50 mg
Development Status:
Ready
Dossier Readiness:
EU registered
ATC Group:
Alimentary tract and metabolism
4B Zone Stability*:
No
Available Territory:
Europe

VORTIOXETINE

Dosage Form:
Film-coated tablet
Dosage Strength:
5 mg, 10 mg, 15 mg, 20 mg
Development Status:
Ongoing
Dossier Readiness:
Q4 2023
ATC Group:
Nervous system
4B Zone Stability*:
Can be added
Available Territory:
Global

DISCLAIMER:

Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83and any other limitation imposed to Zentiva by contracts with 3rd parties . This catalogue shall not constitute an offer for the sale of products and processes for the territories where an offer for sale or sale is not permissible by law orby contracts between Zentiva and 3rd parties. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

*4B Zone stability can be fulfilled upon request if not available at the moment

Contact

Zentiva Group, a.s.
U Kabelovny 529/16
102 00, Prague 10,
Czech Republic

Zent2U@zentiva.com
+420 267 243 231
Copyright Zentiva Group, a.s. © 2022 All rights reserved|created by swallow

Follow us: